Together Pharma Ltd
TGPHF · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.02 | 0.00 | 0.01 |
| FCF Yield | 3.57% | 3.65% | 14.02% | 13.32% |
| EV / EBITDA | 11.87 | 10.17 | 12.88 | 13.13 |
| Quality | ||||
| ROIC | 3.83% | 3.83% | 5.26% | 5.26% |
| Gross Margin | 38.02% | 38.02% | 38.50% | 38.50% |
| Cash Conversion Ratio | 0.61 | 0.61 | -0.98 | -0.98 |
| Growth | ||||
| Revenue 3-Year CAGR | 84.03% | 91.71% | 98.81% | 78.83% |
| Free Cash Flow Growth | 0.00% | -65.09% | 0.00% | 35.02% |
| Safety | ||||
| Net Debt / EBITDA | 6.72 | 5.13 | 8.27 | 8.27 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.24 | 0.24 | 0.25 | 0.25 |
| Cash Conversion Cycle | 317.81 | 317.81 | 317.01 | 317.01 |